Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
Therapy Name | CEP-28122 |
Synonyms | |
Therapy Description |
CEP-28122 is a small molecule inhibitor of ALK that inhibits growth of ALK-positive tumors (PMID: 22203728). |
Drug Name | Trade Name | Synonyms | Drug Classes | Drug Description |
---|---|---|---|---|
CEP-28122 | ALK Inhibitor 32 | CEP-28122 is a small molecule inhibitor of ALK that inhibits growth of ALK-positive tumors (PMID: 22203728). |
Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
---|---|---|---|---|---|---|---|
ALK F1174L | neuroblastoma | sensitive | CEP-28122 | Preclinical - Cell culture | Actionable | In a preclinical study, CEP-28122 inhibited growth of neuroblastoma cells harboring ALK F1174L in culture (PMID: 22203728). | 22203728 |
ALK wild-type | neuroblastoma | resistant | CEP-28122 | Preclinical - Cell culture | Actionable | In a preclinical study, CEP-28122 did not inhibit growth of ALK wild-type neuroblastoma cells in culture (PMID: 22203728). | 22203728 |
ALK negative | leukemia | resistant | CEP-28122 | Preclinical - Cell culture | Actionable | In a preclinical study, CEP-28122 did not inhibit growth of ALK-negative leukemia cells in culture (PMID: 22203728). | 22203728 |
ALK R1275Q | neuroblastoma | sensitive | CEP-28122 | Preclinical - Cell culture | Actionable | In a preclinical study, CEP-28122 inhibited growth of neuroblastoma cells harboring ALK R1275Q in culture (PMID: 22203728). | 22203728 |
ALK amp | neuroblastoma | sensitive | CEP-28122 | Preclinical - Cell culture | Actionable | In a preclinical study, CEP-28122 inhibited growth of ALK-amplified neuroblastoma cells in culture (PMID: 22203728). | 22203728 |
EML4 - ALK | lung non-small cell carcinoma | sensitive | CEP-28122 | Preclinical - Cell line xenograft | Actionable | In a preclinical study, CEP-28122 inhibited growth of non-small cell lung carcinoma cell lines harboring EML4-ALK in culture, and resulted in tumor regression in cell line xenograft models (PMID: 22203728). | 22203728 |
ALK negative | colon carcinoma | resistant | CEP-28122 | Preclinical - Cell line xenograft | Actionable | In a preclinical study, CEP-28122 did not inhibit tumor growth in cell line xenograft models of ALK-negative colon carcinoma (PMID: 22203728). | 22203728 |
ALK negative | lung non-small cell carcinoma | resistant | CEP-28122 | Preclinical - Cell line xenograft | Actionable | In a preclinical study, ALK negative non-small cell lung carcinoma cells were resistant to CEP-28122 in culture and in cell line xenograft models (PMID: 22203728). | 22203728 |
ALK negative | lymphoma | resistant | CEP-28122 | Preclinical - Cell culture | Actionable | In a preclinical study, CEP-28122 did not inhibit growth of ALK-negative lymphoma cells in culture (PMID: 22203728). | 22203728 |
Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
---|